Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

Tesamorelin

Growth hormoneFDA approvedPubMed records: 80count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O Tesamorelin é um análogo sintético de GHRH de 44 aminoácidos, aprovado pela FDA em 2010 sob o nome comercial Egrifta® para o tratamento de lipodistrofia associada ao HIV (acúmulo de gordura visceral abdominal). É um dos poucos peptídeos de GH com aprovação regulatória completa e dados robustos de ensaios clínicos de fase III. Além da redução de gordura visceral, estudos demonstraram benefícios cognitivos e melhora da esteatose hepática (NAFLD). Original in PT-BR

Tesamorelin is catalogued under Growth hormone. 9 Eagle articles in this library reference this compound.

Category
Growth hormone
Research stage
FDA approved — FDA Aprovado (Egrifta®) Original in PT-BR
PubMed records
80 (count from PubMed, not curated)
Eagle articles on this compound
9 Eagle articles

Mechanism

Análogo de GHRH de 44 aminoácidos — reduz gordura visceral via estimulação de GH fisiológico Original in PT-BR

O Tesamorelin liga-se ao receptor de GHRH na pituitária anterior com alta afinidade, estimulando a liberação pulsátil de GH. A liberação de GH resultante promove lipólise (queima de gordura), particularmente na gordura visceral — o depósito de gordura mais metabolicamente ativo e perigoso. Em ensaios clínicos, reduziu a gordura visceral em ~15% em 26 semanas (PMID: 20529952). Diferentemente da administração de GH exógeno, o Tesamorelin mantém o feedback fisiológico, reduzindo o risco de efeitos colaterais de excesso de GH. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
218949-48-5
Molecular formula
C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight
5135,90 g/mol pt-BR notation
Sequence
Modificação N-terminal de trans-3-hexenoic acid + GHRH(1-44) Original in PT-BR
Amino acids
Not recorded in the source.
Solubility
Água bacteriostática, soro fisiológico estéril Original in PT-BR
Stability
Estável reconstituído conforme bula — uso imediato recomendado Original in PT-BR
Half-life
~26 minutos Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
4–12 semanas para redução mensurável de gordura visceral Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

90/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • Ensaio de fase III demonstrou redução de ~15% na gordura visceral em 26 semanas de tratamento diário com 2 mg SC. Aprovação FDA subsequente. Original in PT-BR

    PMID: 20529952Year: 2010Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Adultos mais velhos tratados com Tesamorelin demonstraram melhora significativa em testes de função cognitiva, particularmente memória verbal e função executiva. Original in PT-BR

    PMID: 22170479Year: 2012Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Redução significativa de gordura hepática e melhora de marcadores de esteatose hepática não-alcoólica em pacientes com HIV e NAFLD. Original in PT-BR

    PMID: 25654648Year: 2015Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Reações no sítio de injeção (eritema, prurido, dor)
  • Artralgia
  • Edema periférico

Serious

  • Dados de segurança robustos de ensaios clínicos fase III
  • Hipersensibilidade ao Tesamorelin (raro)

Contraindications

  • Câncer ativo (GH estimula crescimento celular)
  • Gravidez (categoria X)
  • Lesão intracraniana ativa
  • Hipersensibilidade ao manitol (excipiente)

Warnings

  • Monitorar IGF-1 regularmente
  • Pode aumentar retenção hídrica
  • Descontinuação resulta em retorno da gordura visceral

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for Tesamorelin.

Lab tests named in the source

  • IGF-1
  • Glicemia de jejum
  • HbA1c
  • Perfil lipídico
  • ALT/AST
  • DEXA scan (composição corporal)

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
1–2 mg/dia SC Original in PT-BR
Frequência
1x ao dia Original in PT-BR
Rota
SC (abdominal) Original in PT-BR
Ciclo
Contínuo (aprovado para uso prolongado) Original in PT-BR
Timing
Manhã em jejum (30 min antes de comer) Original in PT-BR
Dose FDA
2 mg/dia (Egrifta®) Original in PT-BR

Vial sizes: 2mg · 10mg — Peptide Calculator

Interactions

These relations come from the imported reference material, which records one label and one comment per pair and no source: no PMID, no population or model, no evidence type and no degree of certainty. Eagle did not verify them and does not endorse them. «Compatible», «Caution» and «Avoid» are the imported material's wording, not an Eagle authorisation or prohibition, and none of this is medical advice.

Compatible

Caution

Related

← Back to knowledge area